Document Detail


The no-reflow phenomenon in the coronary circulation.
MedLine Citation:
PMID:  19689256     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The no-reflow phenomenon is a poorly understood complication of percutaneous coronary intervention in which diminished blood flow to distal microvascular beds persists despite the successful treatment of the occlusive lesion from the epicardial coronary artery or arteries. In this contemporary review we endeavour to discuss the pathophysiology of coronary no-reflow, understand the predictors and describe current pharmacological and mechanical strategies to prevent and treat coronary no-reflow.
Authors:
Thomas J Kiernan; Nicholas J Ruggiero; Juan M Bernal; Creighton W Don; Christian Witzke; Gareth D Kiernan; Roberto J Cubeddu; Bryan P Yan
Related Documents :
3343076 - Competition of coronary arteries and ventriculo-coronary arterial communications in pul...
20177986 - Anatomical variants and anomalies of the coronary tree studied with mdct coronary angio...
22912536 - A review of mitral isthmus ablation.
8595626 - Direct visualization of atherosclerosis in small coronary arteries using the epifluores...
9096946 - Valve perforation and balloon pulmonary valvuloplasty in an infant with tetralogy of fa...
15924246 - Symptomatic pleural effusion without intrathoracic migration of ventriculoperitoneal sh...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cardiovascular & hematological agents in medicinal chemistry     Volume:  7     ISSN:  1875-6182     ISO Abbreviation:  -     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-08-19     Completed Date:  2009-10-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101266881     Medline TA:  Cardiovasc Hematol Agents Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  181-92     Citation Subset:  IM    
Affiliation:
Division of Interventional Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. tjkiernan@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenosine / therapeutic use
Animals
Coronary Circulation*
Diltiazem / therapeutic use
Humans
Nicardipine / therapeutic use
Nicorandil / therapeutic use
Nitroprusside / therapeutic use
No-Reflow Phenomenon / drug therapy*,  physiopathology*,  therapy
Prostheses and Implants
Vasodilator Agents / therapeutic use
Verapamil / therapeutic use
Chemical
Reg. No./Substance:
0/Vasodilator Agents; 15078-28-1/Nitroprusside; 42399-41-7/Diltiazem; 52-53-9/Verapamil; 55985-32-5/Nicardipine; 58-61-7/Adenosine; 65141-46-0/Nicorandil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Placental growth hormone, fetal growth and the IGF axis in normal and diabetic pregnancy.
Next Document:  Anticoagulation in patients with heart failure.